UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-41141 GLUCOTRACK, INC. N/A (Former name, former address and former fiscal year, if changed sin ...

For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-41141 GLUCOTRACK, INC. (Exact name of registrant as specified in its charter) Delaware 98-066 ...

FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission file number 000-54785 GLUCOTRACK, INC. (Exact name of registrant as specified in its charter) | Dela ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock | GCTK | NASDAQ Capital Market | Indicate by check mark whether the registrant (1) has filed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock | GCTK | NASDAQ Capital Market | Indicate by check mark whether the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 000-54785 GLUCOTRACK, INC. (Exact name of registrant as specified in its charter) | Delaware | 98 ...

Part I [Business](index=5&type=section&id=Item%201.%20Business.) GlucoTrack, Inc. is a medical device company developing non-invasive glucose monitoring devices, focusing on the advanced GlucoTrack 2.0 for global markets [Overview and Product Development](index=5&type=section&id=Overview%20and%20Product%20Development) The company focuses on developing GlucoTrack 2.0, an advanced wireless non-invasive glucose monitor, for European and U.S. markets - GlucoTrack has developed a non-invasive glucose monitor (GlucoTrack®) that uses a combination of ultrasound, electromagnetic, and thermal technologies to measure glucose levels from the earlobe without drawing blood[22](index=22&type=chunk) - The company is accelerating the development of GlucoTrack 2.0, a wireless and rechargeable ear-clip paired with a smartphone, offering increased accuracy, greater margins, and lower cost compared to the 1.0 model[35](index=35&type=chunk) - The company is now focusing on the U.S. market, planning for FDA clinical trials and building a U.S. go-to-market strategy[37](index=37&type=chunk) [Market Opportunity and Competition](index=8&type=section&id=Market%20Opportunity%20and%20Competition) The substantial global diabetes market presents opportunities, but the company faces intense competition from established and CGM device manufacturers - The International Diabetes Federation estimated that **463 million adults worldwide had diabetes in 2019**, with this number expected to grow to approximately **700 million by 2045**[51](index=51&type=chunk) - The company faces significant competition from four major companies that dominate the self-monitored glucose testing market: Roche, LifeScan (a division of Johnson & Johnson), Abbott Laboratories, and Ascensia[113](index=113&type=chunk) - Continuous Glucose Monitoring (CGM) devices from competitors like Medtronic plc, Abbott Laboratories, and Dexcom, Inc. represent another major competitive threat[115](index=115&type=chunk) [Regulatory and Reimbursement](index=14&type=section&id=Regulatory%20and%20Reimbursement) GlucoTrack 1.0 has EU approval, but U.S. market entry requires FDA approval and securing uncertain third-party reimbursement - GlucoTrack 1.0 received CE Mark approval, allowing it to be marketed and sold in EU member countries, and the company also holds ISO 13485:2016 certification[26](index=26&type=chunk)[28](index=28&type=chunk) - The product has not been approved for commercial sale in the United States, though the FDA confirmed U.S. clinical trials would be considered non-significant risk device studies, allowing them to proceed without an Investigational Device Exemption (IDE) application[86](index=86&type=chunk)[87](index=87&type=chunk) - Commercial success is highly dependent on obtaining reimbursement from third-party payors such as Medicare, Medicaid, and private insurance plans, which is an uncertain and lengthy process[94](index=94&type=chunk)[98](index=98&type=chunk) [Intellectual Property](index=21&type=section&id=Intellectual%20Property) The company proactively protects its technology with 59 issued patents and "GlucoTrack®" trademark registrations in 24 countries - The company holds **59 issued patents** in multiple jurisdictions, including the United States, Europe, China, and Japan, covering its core technology[108](index=108&type=chunk) - Trademark registrations for "GlucoTrack®" have been obtained in **24 countries**, including the US, Europe, and China[110](index=110&type=chunk) [Risk Factors](index=24&type=section&id=Item%201A.%20Risk%20Factors.) Significant risks include operating losses, GlucoTrack 2.0's success dependency, third-party reliance, and internal control weaknesses - The company has a history of operating losses, with a net loss of approximately **$4.0 million in 2021** and an accumulated deficit of **$97.5 million as of December 31, 2021**[127](index=127&type=chunk) - The business is highly dependent on the success of its next-generation product, GlucoTrack® 2.0, which has not yet received regulatory approval or been commercialized[135](index=135&type=chunk) - The company relies on third parties for manufacturing and distribution, which exposes it to risks related to production quality, supply chain disruptions, and sales performance[160](index=160&type=chunk)[164](index=164&type=chunk) - A material weakness was identified in the company's internal control over financial reporting as of December 31, 2021, related to insufficient accounting personnel, lack of segregation of duties, and inadequate internal controls[187](index=187&type=chunk) [Unresolved Staff Comments](index=40&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments.) The company reports no unresolved staff comments - There are no unresolved staff comments[199](index=199&type=chunk) [Properties](index=40&type=section&id=Item%202.%20Properties.) The company leases vehicles and flexible shared workspaces for its principal offices, owning no real estate - The company leases several vehicles with terms expiring between **2023 and 2024**[200](index=200&type=chunk) - Since March 2021, the company rents flexible shared workspaces in Or Yehuda, Israel, on short-term agreements (typically 6 months)[201](index=201&type=chunk) [Legal Proceedings](index=40&type=section&id=Item%203.%20Legal%20Proceedings.) The company is not currently a party to any material litigation - The company reports no material litigation as of the filing date[202](index=202&type=chunk) [Mine Safety Disclosures](index=40&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - This item is not applicable to the company[203](index=203&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=41&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities.) As of March 2022, the company had 358 common stock holders and does not anticipate paying cash dividends - As of March 30, 2022, there were approximately **358 holders of record** of the company's Common Stock[206](index=206&type=chunk) - The company has never paid cash dividends and does not plan to in the foreseeable future[207](index=207&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=41&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Net loss increased in 2021 due to higher R&D and G&A expenses; cash balance is sufficient for 12 months Results of Operations (in thousands of US dollars) | Expense Category | 2021 | 2020 | Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Research & Development | $1,810 | $1,532 | +18.1% | Increase due to slow inventory write-off | | Selling & Marketing | $139 | $415 | -66.5% | Reduced business development expenses pending GlucoTrack® 2.0 | | General & Administrative | $2,091 | $1,185 | +76.4% | Hiring of new and augmented personnel | | **Net Loss** | **$4,067** | **$2,696** | **+50.8%** | Primarily due to increased G&A and R&D expenses | - As of December 31, 2021, the company had cash on hand of **$6,062 thousand** and believes this is sufficient to meet its capital needs for at least 12 months[226](index=226&type=chunk) Net Cash Flow Summary (in thousands of US dollars) | Cash Flow Activity | 2021 | 2020 | | :--- | :--- | :--- | | Net Cash Used in Operating Activities | ($3,769) | ($3,501) | | Net Cash Used in Investing Activities | ($1) | ($53) | | Net Cash Provided by Financing Activities | $0 | $13,009 | [Controls and Procedures](index=46&type=section&id=Item%209A.%20Controls%20and%20Procedures.) Disclosure controls were ineffective in 2021 due to material weaknesses in internal control, with remediation planned - Management concluded that disclosure controls and procedures were ineffective as of December 31, 2021[237](index=237&type=chunk) - Material weaknesses were identified related to a lack of sufficient internal accounting personnel, inadequate segregation of duties, and insufficient internal controls for complex and non-routine transactions[238](index=238&type=chunk) - Management has identified corrective actions, including hiring additional employees, and intends to implement remediation procedures during fiscal year 2022[239](index=239&type=chunk) Part III [Directors, Executive Officers, Corporate Governance, Compensation, and Related Transactions](index=46&type=section&id=Items%2010-14) Information for Items 10-14 is incorporated by reference from the company's definitive proxy statement - Information for Items 10, 11, 12, 13, and 14 is incorporated by reference from the company's definitive Proxy Statement[245](index=245&type=chunk)[248](index=248&type=chunk)[249](index=249&type=chunk)[250](index=250&type=chunk)[251](index=251&type=chunk) Part IV [Exhibits, Financial Statement Schedules](index=48&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules.) This section lists financial statements, schedules, and exhibits filed with the Form 10-K report - This section provides a list of all exhibits filed with the Form 10-K, including corporate governance documents, material contracts, and certifications[253](index=253&type=chunk)[255](index=255&type=chunk)[256](index=256&type=chunk) Financial Statements [Consolidated Financial Statements](index=52&type=section&id=Consolidated%20Financial%20Statements) 2021 financial statements show decreased assets, increased net loss, and an inventory write-down due to strategic shift Consolidated Balance Sheet Data (in thousands of US dollars) | Account | Dec 31, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | Cash and cash equivalents | $6,062 | $9,823 | | Total Assets | $6,265 | $10,606 | | Total Liabilities | $1,110 | $1,624 | | Total Stockholders' Equity | $5,155 | $8,982 | | Accumulated Deficit | ($97,466) | ($93,399) | Consolidated Statement of Operations Data (in thousands of US dollars) | Account | 2021 | 2020 | | :--- | :--- | :--- | | Total operating expenses | $4,040 | $3,132 | | Operating loss | ($4,040) | ($3,132) | | Loss for the year | ($4,067) | ($2,696) | | Loss per share (Basic and Diluted) | $0.26 | $0.19 | - In the fourth quarter of 2021, the company recorded an inventory write-down of approximately **$321 thousand** as the development of its second-generation device rendered the existing inventory obsolete[345](index=345&type=chunk) - The company has an outstanding contingent liability to the Israeli Innovation Authority (IIA) for royalties on future sales, amounting to approximately **$43 thousand plus interest**[356](index=356&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 000-54785 INTEGRITY APPLICATIONS, INC. (Exact name of registrant as specified in its charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 000-54785 INTEGRITY APPLICATIONS, INC. (Exact name of registrant as specified in its charter) | De ...

[PART I - FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements.) This section presents the unaudited condensed consolidated financial statements for the three-month period ended March 31, 2021, including the balance sheet, statement of operations, statement of changes in stockholders' equity, and statement of cash flows, reporting a net loss of **$904 thousand** and **$8.9 million** in cash and cash equivalents [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$9.6 million** from **$10.6 million** at year-end 2020, primarily due to reduced cash and cash equivalents, with total liabilities falling to **$1.5 million** and stockholders' equity to **$8.1 million** Condensed Consolidated Balance Sheet Highlights (in thousands of US dollars) | Account | March 31, 2021 (Unaudited) | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | 8,887 | 9,823 | | Total current assets | 9,280 | 10,229 | | **TOTAL ASSETS** | **9,628** | **10,606** | | **Liabilities & Equity** | | | | Total Current Liabilities | 1,248 | 1,345 | | Total Liabilities | 1,479 | 1,624 | | Total Stockholders' equity | 8,149 | 8,982 | | **TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY** | **9,628** | **10,606** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The company reported no revenue and a net loss of **$904 thousand** for the three months ended March 31, 2021, an increase from **$734 thousand** in 2020, primarily due to higher general and administrative expenses Condensed Consolidated Statements of Operations (in thousands of US dollars) | Account | Three-month period ended March 31, 2021 | Three-month period ended March 31, 2020 | | :--- | :--- | :--- | | Research and development expenses | 309 | 413 | | Selling and Marketing | 23 | 91 | | General and administrative expenses | 564 | 252 | | **Total operating expenses** | **896** | **756** | | **Operating loss** | **896** | **756** | | **Loss for the period** | **904** | **734** | | **Comprehensive Loss for the period** | **882** | **715** | | Loss per share (Basic and Diluted) | (0.00) | (0.00) | [Condensed Consolidated Statement of Changes in Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Stockholders'%20Equity) Stockholders' equity decreased from **$9.0 million** to **$8.1 million** as of March 31, 2021, primarily due to the **$904 thousand** net loss incurred during the quarter, partially offset by other comprehensive income and stock-based compensation Changes in Stockholders' Equity for Q1 2021 (in thousands of US dollars) | Description | Amount | | :--- | :--- | | Balance as of January 1, 2021 | 8,982 | | Loss for the period | (904) | | Other comprehensive income | 22 | | Stock-based compensation | 49 | | **Balance as of March 31, 2021** | **8,149** | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$933 thousand** for Q1 2021, with no investing or financing activities, contrasting with **$13.0 million** in financing cash inflow in Q1 2020, leading to a decrease in cash, cash equivalents, and restricted cash from **$9.9 million** to **$9.0 million** Condensed Consolidated Statements of Cash Flows (in thousands of US dollars) | Cash Flow Activity | Three-month period ended March 31, 2021 | Three-month period ended March 31, 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | (933) | (989) | | Net cash used in investing activities | - | (15) | | Net cash provided by financing activities | - | 13,009 | | **Change in cash, cash equivalents, and restricted cash** | **(932)** | **12,002** | | Cash, cash equivalents, and restricted cash at end of the period | 8,953 | 12,478 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes confirm the company's ability to operate as a going concern for at least 12 months with **$8.9 million** in cash, detail its focus on non-invasive glucose monitoring device development, and outline significant accounting policies and operating lease liabilities - The company expects its cash and cash equivalents of approximately **$8.9 million** as of March 31, 2021, to be sufficient to meet its capital needs for at least 12 months, allowing it to operate as a going concern[24](index=24&type=chunk) - The company's subsidiary, Integrity Israel, focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for people with diabetes and prediabetes[25](index=25&type=chunk) - As of March 31, 2021, total future operating lease payments amount to **$163 thousand**, with a present value of **$149 thousand**[37](index=37&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=12&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses the company's non-invasive glucose monitor, GlucoTrack®, including CE Mark approval and self-calibration, reporting no revenue for Q1 2021, a net loss of **$904 thousand** (up from **$734 thousand**), and **$8.9 million** in cash, deemed sufficient for over a year [Overview](index=12&type=section&id=Overview) The company, a medical device firm, focuses on its non-invasive glucose monitor, GlucoTrack®, with CE Mark approval and recent self-calibration enhancements, while developing companion apps and a cloud-based platform for future data-driven revenue streams - The company's primary product is the GlucoTrack® model DF-F, a non-invasive blood glucose monitor that uses ultrasound, electromagnetic, and thermal technologies via an earlobe clip[40](index=40&type=chunk) - Key product enhancements have received CE Mark approval, simplifying the calibration process from 3 hours monthly to 30 minutes every six months, which can now be performed by the user at home[43](index=43&type=chunk)[44](index=44&type=chunk)[45](index=45&type=chunk) - Future strategy includes developing companion applications and a cloud-based solution to provide personalized diabetes management tools and monetize de-identified user data[41](index=41&type=chunk) [Results of Operations](index=15&type=section&id=Results%20of%20Operations) For Q1 2021, the company reported no revenue, with total operating expenses increasing to **$896 thousand** from **$756 thousand** due to a rise in general and administrative expenses from **$252 thousand** to **$564 thousand**, resulting in a widened net loss of **$904 thousand** from **$734 thousand** year-over-year Comparison of Operating Results (in thousands of US dollars) | Account | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Revenues | 0 | 0 | | Research and development expenses | 309 | 413 | | Selling and marketing expenses | 23 | 91 | | General and administrative expenses | 564 | 252 | | **Net Loss** | **904** | **734** | - The increase in general and administrative expenses is primarily attributable to the hiring of new and augmented personnel to advance the company's business agenda[58](index=58&type=chunk) [Liquidity and Capital Resources](index=16&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2021, the company held approximately **$8.9 million** in cash from a **$15 million** private placement, which management deems sufficient for over one year of operations, with net cash used in operating activities at **$933 thousand** for the quarter - The company had cash on hand of approximately **$8.9 million** as of March 31, 2021[62](index=62&type=chunk) - Management believes current cash and cash equivalents will enable operations for a period exceeding one year from the report date[62](index=62&type=chunk) Net Cash Flow Summary (in thousands of US dollars) | Cash Flow Activity | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Net Cash Used in Operating Activities | (933) | (989) | | Net Cash Used in Investing Activities | 0 | (15) | | Net Cash Provided by Financing Activities | 0 | 13,009 | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=17&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) As a smaller reporting company, the company is not required to provide quantitative and qualitative disclosures about market risk - Disclosure is not required for smaller reporting companies[67](index=67&type=chunk) [Item 4. Controls and Procedures](index=17&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2021, with no material changes in internal control over financial reporting during the quarter - Based on an evaluation as of March 31, 2021, the President and Interim CFO concluded that the company's disclosure controls and procedures were effective at the reasonable assurance level[68](index=68&type=chunk) - No changes occurred in the company's internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, these controls[69](index=69&type=chunk) [PART II - OTHER INFORMATION](index=18&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=18&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section discloses a private placement on February 14, 2020, involving the sale of **37,500,000 shares** for **$15 million** in gross proceeds, with the placement agent receiving **$1.95 million** in fees and a warrant to purchase **3,750,000 shares** - On February 14, 2020, the company entered into a Securities Purchase Agreement with an accredited investor, selling **37,500,000 shares** for a gross purchase price of **$15,000 thousand**[71](index=71&type=chunk) - In Q1 2020, the placement agent, Andrew Garrett, was paid **$1,950 thousand** in fees and issued a warrant to purchase **3,750,000 shares**[72](index=72&type=chunk) [Item 6. Exhibits](index=18&type=section&id=Item%206.%20Exhibits.) This section lists exhibits filed with the Form 10-Q report, including certifications from the Principal Executive Officer and Financial Officer under Sarbanes-Oxley Act Sections 302 and 906, and various XBRL data files - The report includes certifications from the Principal Executive and Financial Officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[73](index=73&type=chunk) - XBRL Instance, Schema, Calculation, Label, Presentation, and Definition documents are included as exhibits[73](index=73&type=chunk)